LeMaitre Vascular (LMAT) Expected to Announce Earnings on Wednesday

LeMaitre Vascular (NASDAQ:LMAT) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.6860 per share and revenue of $67.39 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The firm had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. The company’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.60 EPS. On average, analysts expect LeMaitre Vascular to post $2.89 EPS for the current fiscal year and $3.18 EPS for the next fiscal year.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded up $0.40 during trading hours on Wednesday, reaching $84.19. 12,288 shares of the company’s stock were exchanged, compared to its average volume of 274,399. The company has a market cap of $1.93 billion, a P/E ratio of 29.53 and a beta of 0.48. LeMaitre Vascular has a 1 year low of $78.22 and a 1 year high of $118.01. The company’s 50 day moving average is $81.17 and its two-hundred day moving average is $94.21.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Wells Fargo & Company cut their price objective on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 5th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Finally, Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular has an average rating of “Hold” and an average price target of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.